Overview
AMP-activated protein kinase (AMPK) is a phylogenetically ancient heterotrimeric serine/threonine kinase that functions as the cell's primary energy sensor. When the cellular energy state falls — AMP and ADP rise relative to ATP — AMPK is activated, switching metabolism from ATP-consuming anabolic processes to ATP-generating catabolic processes. It is expressed in virtually all eukaryotic cells and acts as a signalling nexus for exercise, fasting, caloric restriction, and numerous metabolic diseases.
AMPK activation has two components: allosteric activation (AMP binds γ-subunit CBS domains → conformational change → activates kinase domain; blocks dephosphorylation of Thr172) and covalent activation (LKB1 or CaMKKβ phosphorylates α-subunit Thr172 → 100–1000-fold kinase activity increase). In the liver, the tumour suppressor LKB1 (STK11) is the dominant upstream kinase. In the hypothalamus and neurons, CaMKKβ (Ca²⁺/calmodulin-dependent kinase kinase β) responds to Ca²⁺ rises to activate AMPK — linking neural activity to energy state.
AMPK's physiological importance is underscored by the fact that metformin, the world's most widely prescribed antidiabetic drug, acts primarily through AMPK (by inhibiting mitochondrial Complex I → ↑AMP/ATP ratio → LKB1-mediated Thr172 phosphorylation). Exercise also activates AMPK in skeletal muscle via AMP/ADP rise and CaMKKβ, explaining many beneficial metabolic effects of physical activity.
Structure — αβγ Heterotrimer
| Subunit | Isoforms | Domain | Function |
|---|---|---|---|
| α (catalytic) | α1 (PRKAA1), α2 (PRKAA2) | N-terminal kinase domain + C-terminal regulatory domain (AIS + αRIM) | Kinase active site; Thr172 in activation loop (must be phosphorylated for activity); α2 nuclear localisation signal; αRIM contacts γ AMP-site for allosteric regulation |
| β (scaffold) | β1 (PRKAB1), β2 (PRKAB2) | N-terminal myristoylation + carbohydrate-binding module (CBM) + C-terminal αγ-subunit binding | Tethers α and γ; CBM senses glycogen (high glycogen → AMPK inhibited, cannot bind glycogen particle and LKB1 simultaneously); β2 expressed in skeletal muscle |
| γ (regulatory) | γ1 (PRKAG1), γ2 (PRKAG2), γ3 (PRKAG3) | 4 CBS (cystathionine β-synthase) domains forming 2 Bateman domains | Binds AMP, ADP, ATP at CBS3 and CBS1; AMP binding: allosteric activation + protection of Thr172 from PP2C/PP2A dephosphorylation; γ2/γ3 mutations → Wolff-Parkinson-White (hypertrophic cardiomyopathy + pre-excitation) |
Human AMPK exists as 12 possible αβγ heterotrimer combinations (2α × 2β × 3γ), each with distinct subcellular localisation and tissue expression. The most abundant complexes in metabolic tissues: α1β1γ1 (ubiquitous); α2β2γ1 (skeletal muscle); α1β1γ2 (liver, heart).
Mechanism — Energy Sensing & Downstream Targets
┌──────────────────────────────────────────────────────────────────────┐ │ AMPK ACTIVATION — ENERGY SENSING │ │ │ │ LOW ENERGY STATE: │ │ Exercise / Fasting / Hypoxia / Metformin (Complex I inhibitor) │ │ │ │ │ ATP consumed → ADP rises → adenylate kinase: 2 ADP ⇌ ATP + AMP │ │ AMP/ATP ratio rises (AMP rises 10-50× before ATP falls) │ │ │ │ │ AMP binds γ-CBS domains → AMPK conformation change │ │ │ │ │ Two concurrent activation mechanisms: │ │ ┌─────────────────────┬───────────────────────────┐ │ │ ALLOSTERIC COVALENT ACTIVATION │ │ │ (AMP → γ-subunit) (LKB1 or CaMKK2 → α-Thr172) │ │ │ ↑kinase 2–5× ↑kinase 100–1000× │ │ │ │ │ │ AMP also protects Thr172-P from PP2C dephosphorylation │ │ │ │ LKB1 (liver kinase B1 / STK11): │ │ constitutively active; forms complex with STRAD + MO25 │ │ cytoplasmic; dominant upstream kinase in liver, epithelial cells │ │ tumour suppressor (Peutz-Jeghers syndrome = LKB1 mutation) │ │ │ │ CaMKKβ (calcium/calmodulin-dependent protein kinase kinase β): │ │ activated by ↑[Ca²⁺] (muscle contraction, neural activity) │ │ dominant in hypothalamus, neurons, T-cells; AMP-independent │ │ leptin → hypothalamic Ca²⁺ → CaMKKβ → AMPK → ↓food intake │ │ │ ├──────────────────────────────────────────────────────────────────────┤ │ AMPK SUBSTRATE TARGETS │ │ │ │ ANABOLIC pathways INHIBITED: │ │ ───────────────────────────── │ │ ACC1/ACC2 (acetyl-CoA carboxylase Ser79/Ser221) │ │ → ↓malonyl-CoA → CPT1 de-inhibited → ↑mitochondrial FA import │ │ → ↑β-oxidation; also ↓fatty acid synthesis (↓ACC1→↓palmitate) │ │ │ │ HMGCR (HMG-CoA reductase Ser872) → ↓cholesterol synthesis │ │ │ │ Raptor (component of mTORC1) → ↓mTORC1 → ↓protein synthesis, │ │ ↓S6K1, ↓4E-BP1 → ↓ribosome biogenesis │ │ [also via TSC2 Ser1387: ↑TSC2 GTPase → ↓Rheb → ↓mTORC1] │ │ │ │ CREB-regulated transcription coactivator 2 (CRTC2) / TORC2 │ │ → ↓gluconeogenic gene expression (PEPCK, G6Pase) in liver │ │ [note: glucagon PKA activates CRTC2 — opposite to AMPK] │ │ │ │ GPAT1 (glycerol-3-phosphate acyltransferase) → ↓TG synthesis │ │ │ │ CATABOLIC pathways ACTIVATED: │ │ ───────────────────────────── │ │ ULK1 (unc-51-like kinase 1 Ser317/Ser777) → ↑autophagy │ │ [mTOR phosphorylates ULK1-Ser757 → blocks autophagy: │ │ AMPK and mTOR antagonistically control ULK1] │ │ │ │ PGC-1α (Thr177/Ser538) + SIRT1 → ↑mitochondrial biogenesis │ │ → ↑OXPHOS capacity, ↑UCP3 (exercise adaptation) │ │ │ │ eNOS (Ser1177) → ↑endothelial NO → vasodilation │ │ (exercise → AMPK → eNOS → NO → ↑blood flow to muscle) │ │ │ │ GLUT4 translocation → ↑skeletal muscle glucose uptake │ │ (insulin-independent pathway — critical in T2D) │ │ │ │ TFEB (transcription factor EB) → ↑lysosomal biogenesis │ └──────────────────────────────────────────────────────────────────────┘
- Energy stress (exercise, fasting, ischaemia, heat shock) → ATP consumption → adenylate kinase equilibrium → AMP and ADP accumulate. AMP binds to γ-subunit CBS3 site; ADP binds CBS1 — both protect Thr172-P from phosphatase.
- LKB1–STRAD–MO25 complex constitutively phosphorylates AMPK α-Thr172 but PP2C continually removes this phosphate unless AMP/ADP is elevated; net effect is AMP-controlled Thr172 phospho-status.
- ACC phosphorylation is the canonical AMPK readout: ACC2 Ser221 phosphorylation in mitochondria-associated membrane → ↓malonyl-CoA → CPT1A/CPT1B de-inhibited → fatty acyl-CoA import into matrix → β-oxidation. ACC1 Ser79 → ↓cytoplasmic malonyl-CoA → ↓de novo fatty acid synthesis.
- mTORC1 suppression (via Raptor + TSC2): blocks protein synthesis and ribosome biogenesis — a major energy conservation strategy in nutrient deprivation; also critical link between AMPK and autophagy induction (AMPK activates ULK1; mTOR inhibits ULK1).
- PGC-1α phosphorylation + SIRT1 (NAD⁺-dependent deacetylase, also activated in low-energy state) → PGC-1α activated → OXPHOS gene upregulation → mitochondrial biogenesis → long-term adaptive increase in energy production capacity.
- GLUT4 translocation: AMPK → AS160 (Rab-GTPase-activating protein) Thr642 phosphorylation → Rab10 → GLUT4 vesicle fusion with plasma membrane — insulin-independent glucose uptake; persists even when insulin signalling is impaired (T2D).
Physiological Roles
| Context | AMPK Response | Net Effect |
|---|---|---|
| Aerobic exercise (skeletal muscle) | ↑AMP/ATP, ↑Ca²⁺/CaMKKβ → AMPK | ↑fatty acid oxidation, ↑GLUT4, ↑mitochondrial biogenesis (adaptation), ↑eNOS → muscle vasodilation |
| Fasting / caloric restriction | ↑AMP/ADP, ↓insulin → AMPK (liver, adipose) | ↓lipid synthesis, ↓cholesterol synthesis, ↑autophagy, ↑gluconeogenesis (via HGP, limited in acute) |
| Hypoxia (ischaemia) | Mitochondrial electron transport blocked → rapid AMP rise | ↑glycolysis (through HIF-1α), ↑autophagy; cardiac preconditioning via AMPK; ischaemia-induced GLUT1 translocation |
| Hypothalamic food intake | Fasting → AMPK in ARC/VMH | ↑NPY/AgRP (orexigenic); leptin and insulin INHIBIT hypothalamic AMPK → satiety (opposite to peripheral AMPK) |
| Immune function (macrophage) | LPS/IL-6 → AMPK → anti-inflammatory | AMPK inhibits NFκB (via IKK-β), ↓iNOS, ↓IL-1β, ↑IL-10; resolves inflammation after initial response |
| β-cell glucose sensing | High glucose → ↑ATP → AMPK inhibited | AMPK inhibition at high glucose facilitates KATP closure → depolarisation → insulin secretion; AMPK activation at low glucose → reduces exocytosis |
Pharmacology & Clinical Use
Metformin (biguanide) — indirect AMPK activator via Complex I inhibition in liver mitochondria → ↑AMP → LKB1 → AMPK → ↓PEPCK/G6Pase (gluconeogenesis) + ↓ACC2 + ↓HMGCR. Also AMPK-independent effects: direct inhibition of Complex IV, mitochondrial glycerophosphate dehydrogenase, and mTORC1 (via Rag GTPase pathway). First-line T2D drug globally; also studied in longevity, cancer prevention (TAME trial), PCOS. Contraindicated in eGFR <30 (lactic acidosis risk — lactate production increased when Complex I is inhibited and not cleared by liver).
AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) — converted intracellularly to AICA ribonucleotide (ZMP), an AMP mimetic that allosterically activates AMPK; research tool; not approved but used in ex vivo exercise research and cardiac ischaemia models.
Direct AMPK activators — A-769662 (Abbott Laboratories; synthetic allosteric β1-subunit activator at the ADaM site between α and β CBM domains); MK-8722 (Merck; pan-AMPK activator; lowered glucose but caused cardiac hypertrophy in rodents via AMPK-α2 — safety concern); PF-739 (Pfizer). All face challenge of tissue selectivity — hepatic AMPK activation beneficial; hypothalamic AMPK activation → increased food intake.
Exercise mimetics — no approved drug fully replicates exercise AMPK activation in muscle; GW501516 (PPARδ agonist with AMPK activation) showed cancer risk in animal studies — abandoned. Exercise itself remains the most clinically effective AMPK activator.
Pathology
| Condition | AMPK Dysregulation | Mechanism & Consequence |
|---|---|---|
| Type 2 diabetes | Reduced hepatic AMPK activity | Ectopic lipid → IKKβ + ceramide → LKB1 S431 phosphorylation (less nuclear STRAD interaction) → ↓LKB1 activity → ↓AMPK → unrestrained hepatic gluconeogenesis; metformin restores |
| NASH / MAFLD | Reduced AMPK-ACC signalling | ↑ACC2 activity → ↑malonyl-CoA → ↓CPT1 → ↓β-oxidation → hepatic lipid accumulation; ↑DNL (ACC1); AMPK activators (metformin, semaglutide, resmetirom) are therapeutic |
| Peutz-Jeghers syndrome (STK11) | Complete LKB1 loss | Germline STK11 mutation → LKB1 protein absent → AMPK cannot be activated by AMP → mTORC1 constitutively active → unchecked growth → GI polyposis + high GI/pancreatic/breast cancer risk; mTOR inhibitors (rapalogs) explored |
| Wolff-Parkinson-White + HCM (PRKAG2) | γ2 gain-of-function | PRKAG2 mutations (R302Q, N488I) → constitutively active AMPK-γ2 → ↑glucose uptake → glycogen accumulation in cardiac myocytes → pre-excitation + HCM; mimics Pompe disease but glycogen content is normal amylopectin |
| Cancer | LKB1/AMPK loss in tumours | LKB1 is mutated in ~20% NSCLC, pancreatic cancer → unrestrained mTORC1 → anabolic drive; AMPK loss also reduces cell polarity and tight junction maintenance → metastasis permissive |
| Heart failure (ischaemic) | AMPK protective → activated during ischaemia | Cardiac AMPK-α2 → ↑GLUT1/4 translocation → ↑anaerobic glycolysis during ischaemia (protective); sustained AMPK activation in HF → ↑fatty acid oxidation can increase O₂ demand — complex role depending on cardiac energy substrate preference |
Connections
AMPK is upstream of mTORC1 (anabolism switch), autophagy (ULK1), mitochondrial biogenesis (PGC-1α/SIRT1), lipid metabolism (ACC/HMGCR), gluconeogenesis (CRTC2/TORC2), nitric oxide production (eNOS), and glucose transport (GLUT4/AS160). It is the key molecular mechanism linking exercise, fasting, and caloric restriction to improved metabolic health. AMPK opposes the glucagon–cAMP–PKA axis (glucagon inhibits AMPK in liver via PKA Ser485 phosphorylation on α-subunit). Leptin activates hypothalamic AMPK via CaMKKβ (context: NPY/AgRP neurons — but overall leptin is anorexigenic, suppressing AMPK in feeding-relevant POMC neurons — highly context-dependent).
References
- Hardie DG, Ross FA, Hawley SA (2012). AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 13:251–262.
- Lin S-C, Hardie DG (2018). AMPK: sensing glucose as well as cellular energy status. Cell Metab 27:299–313.
- Hawley SA et al. (2003). Complexes between the LKB1 tumor suppressor, STRAD, and MO25 and their role in the regulation of cell polarity. Science 302:456–460.
- Shaw RJ et al. (2005). The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310:1642–1646.
- Foretz M et al. (2014). Metformin: from mechanisms of action to therapies. Cell Metab 20:953–966.
- Carling D et al. (2012). AMP-activated protein kinase: new regulation, new roles? Biochem J 445:11–27.
- Steinberg GR, Hardie DG (2023). New insights into activation and function of the AMPK. Nat Rev Mol Cell Biol 24:255–272.